Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop ...

Eli Lilly (LLY 3.74%) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in ...

It’s the latest move in the race by drug companies to corner more of the highly-lucrative obesity drug market.

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Alpha Wealth Funds, LLC, an investment management company, released its Q3 2025 letter for the “Insiders Fund”. A copy of the ...

Eli Lilly stays a Strong Buy as GLP-1 demand drives revenue/EPS beats, margin gains, and pipeline upside. Click here to read ...

Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks ...

Nimbus Therapeutics said on Tuesday it has entered into a multi-year research and licensing agreement with Eli Lilly to ...

Arrowhead’s experimental therapy helped patients on Lilly’s Zepbound lose more weight and visceral fat—but cost and ...

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

Nimbus will use its AI to help identify drug candidates, while Lilly will contribute its metabolic-disease expertise to ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...